# Giuseppe Curigliano

Source: https://onco.cc/people/giuseppe-curigliano/  
OnCo record `giuseppe-curigliano` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Breast oncologist and phase 1 leader who co-led DESTINY-Breast06 and shaped the HER2-low concept.

## Summary

Giuseppe Curigliano is Director of the Early Drug Development Division at IEO, the European Institute of Oncology, in Milan and Professor of Medical Oncology at the University of Milan, and chairs guideline committees for the European Society for Medical Oncology (ESMO). His specialisms are breast cancer, early drug development, HER2-low disease and cardio-oncology. He is a principal investigator in the DESTINY-Breast programme of trastuzumab deruxtecan and helped shape the HER2-low concept. His New England Journal of Medicine paper on DESTINY-Breast06 reported trastuzumab deruxtecan in HER2-low or HER2-ultralow, hormone receptor-positive metastatic breast cancer. His publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Early Drug Development Division, IEO; Professor of Medical Oncology, University of Milan
- Specialisms: Breast cancer; Early drug development; HER2-low disease; Cardio-oncology

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Curigliano%20G%5BAuthor%5D%20breast%20deruxtecan

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [HER2](https://onco.cc/targets/her2/)
- drugs: [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- institutions: [European Society for Medical Oncology (ESMO)](https://onco.cc/institutions/esmo/), [Fondazione AIRC per la ricerca sul cancro](https://onco.cc/institutions/airc/), [IEO (European Institute of Oncology)](https://onco.cc/institutions/ieo-milan/)
- terms: [HER2-low and HER2-ultralow](https://onco.cc/terms/her2-low/)
- trials: [DESTINY-Breast06](https://onco.cc/trials/destiny-breast06/)
- key papers: [DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer](https://onco.cc/key-papers/paper-destiny-breast03-nejm-2022/), [DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer](https://onco.cc/key-papers/paper-destiny-breast06-nejm-2024/), [Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline](https://onco.cc/key-papers/paper-bedrosian-asco-sso-germline-testing-breast-jco-2024/), [Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy](https://onco.cc/key-papers/paper-park-tils-untreated-early-tnbc-ann-oncol-2019/), [Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer](https://onco.cc/key-papers/paper-st-gallen-2025-consensus-ann-oncol-2025/), [Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer](https://onco.cc/key-papers/paper-leon-ferre-tils-tnbc-no-chemotherapy-jama-2024/), [Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023](https://onco.cc/key-papers/paper-st-gallen-2023-consensus-ann-oncol-2023/), [Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline](https://onco.cc/key-papers/paper-esmo-mbc-living-guideline-update-ann-oncol-2025/)
- roadmaps: [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/giuseppe-curigliano.json